Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Waverley Expands UK Cancer Portfolio

Marketing Authorizations Obtained For Erlotinib Tablets

Executive Summary

Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.

You may also be interested in...

Waverley Lists In Frankfurt

Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.

Products Roundup – 26 March 2019

The latest generic, biosimilar and value-added drug development news and highlights from across the globe.

Waverley buys two in the UK

Canada’s Waverley Pharma has acquired two UK oncology generics, capecitabine and temozolomide, from Reliance Life Sciences. “The products were developed by Reliance Life Sciences and the binding contracts with the UK National Health Service (NHS) for the supply of these products are being transferred to Waverley Pharma,” the firm noted.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts